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ABSTRACT
Objective: To determine the predictors of concomitant use of benzodiazepines with
chronic opioid use in Rhode Island using pharmacy level data.
Design: Cross – sectional analysis
Setting: Rhode Island Prescription Drug Monitoring Program (PDMP) Database, 2015
Participants: Any person who filled a prescription for an opioid (>30 days’ supply), a
benzodiazepine or both at a licensed retail pharmacy in Rhode Island during 2015.
Main outcome measure: Concomitant use of opioid analgesics and benzodiazepines,
defined as the receipt of any benzodiazepine and opioid pharmacy dispensing having a
days’ supply which overlaps by at least 1 day.
Results: Of 139,410 patients who were included in our analysis, 15.5% had overlapping
(concomitant) opioid and benzodiazepine prescriptions during 2015. Patients who were
younger than 45 years of age, and who see more than three prescribers were less likely
to be prescribed both opioids and benzodiazepines, in which the days supply overlap.
Additionally, each additional prescription a person receives for a controlled substance
increased the odds that they were prescribed concomitant therapy.
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CHAPTER 1

INTRODUCTION

In August, 2016, the Food and Drug Administration (FDA) published a drug
safety communication warning of the serious risks associated with the concomitant use
of opioids and benzodiazepines after published literature identified an increase in the
combined use of these central nervous system depressant drugs. 1 Combined use of
these two classes of drugs may lead to respiratory depression, coma and even death,
which are all side effects that may be avoided if proper prescribing and usage
guidelines are respected. 1
Since 2014, Rhode Island has maintained a fully operational Prescription Drug
Monitoring Database (PDMP), which captures medication dispensing of controlled
substances, as reported by pharmacists. This study measured the extent of concomitant
use of opioid and benzodiazepine medications and determined if patients prescribed
both of these types of medications differ from patients using opioids solely,
benzodiazepines solely, and opioids and benzodiazepines with no overlapping days of
use, with regard to demographics, insurance type, and use of other controlled
substances.
Hypothesis:
1. Patient demographics, number of prescribers, number of pharmacies
utilized, total number of prescriptions filled, and stimulant use does not
differ between those who concomitantly use opioids and benzodiazepines
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and those who solely use opioids or benzodiazepines, or those who have
dual, non-overlapping use of benzodiazepines and opioids.
2. Among those who concomitantly use opioids and benzodiazepines, the

following factors are not predictors of increased risk: opioid type, average
number of prescriptions by duration of action, average number of
controlled substance prescriptions by class, average days of supply by class
and number of prescribers.
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CHAPTER 2

REVIEW OF LITERATURE

It has been widely publicized that the United States is experiencing an opioid
addiction and overdose epidemic. In a NCHS data brief from 2014, it was noted that
opioid analgesic poisoning (intentional and unintentional) accounted for 41% of drug
poisoning deaths in 2011. This number represents 16,917 deaths, a 300% increase
from 1999.2 As of 2009, drug poisoning deaths surpassed traffic accidents as the
leading cause of injury related deaths for the first time since 1980.3
Opioids are used to treat a wide range of pain experiences, from severe pain
associated with cancer to moderate to severe pain associated with neuropathy,
fibromyalgia, headaches, and musculoskeletal disorders. Opioids are, therefore,
prescribed to a wide range of individuals. From 2000 to 2010, there was 104%
increase in the number of opioid analgesic prescriptions written: 89.2 million
prescriptions. The number of patients receiving opioid prescriptions increased 80% in
this same time period, to 27.5 million individuals.4 While there has been an increase in
both the number of patients receiving prescriptions for opioids and the total number of
prescriptions written, there is evidence to suggest being prescribed opioids did little to
improve the health and disability status of the patient, as health status remained
unchanged or actually decreased.4
Safely and effectively managing acute and chronic pain in a patient with
comorbid conditions presents challenges. While it may inappropriate to use opioids in
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conjunction with a variety of medication classes, combined use with benzodiazepines
is particularly perilous. Jones, et al, analyzed 2010 overdose data for the United States,
and found that among overdose deaths involving an opioid analgesic, benzodiazepines
were also involved in 30% of cases.5 In another study, conducted by Yarbourgh, et al,
the researchers analyzed interviews with survivors of opioid overdoses and found that
most events involved the use of multiple drugs (83%), and often benzodiazepines
(32%).6 Reisfield, et al, noted that opioids and benzodiazepines are the most
commonly co-abused drugs; estimates ranging from 20-50% of patients who are
prescribed long term opioid therapy, also received prescriptions for a benzodiazepine.7
The concomitant use of opioids with benzodiazepines is discouraged in
prescribing guidelines,8 but co-prescribing these drugs by both a single prescriber or
simultaneously by multiple prescribers is not uncommon, nor is prescribing for a
longer duration than is recommended.9 This may be due to the fact that
benzodiazepines are characterized as relatively safe while having a high therapeutic
index,10 and less likely than opioids to be the sole drug involved in an accidental
overdose.11 Benzodiazepines are recommended as a second-line treatment for some
common conditions such as insomnia, and anxiety, and when they are prescribed it is
recommended that they are used for a short time period and not in conjunction with
certain other classes of medicines, including opioids. Benzodiazepines alter the
pharmacodynamic effects of opioids. Studies have shown that the concomitant use
amplifies the central nervous system effects of opioids.12 Additionally, opioids and
benzodiazepines have different mechanisms of action which is problematic because
both opioids and benzodiazepines are central nervous system depressants; these drugs
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have the effect of depressing the central nervous system through two different
mechanisms when the two classes of drugs are administered together.11 This can lead
to overdose; chronic use of both opioids and benzodiazepines has been associated with
“additive effects in sleep disordered breathing.”13 Finally, when benzodiazepines are
prescribed for a longer period than is recommended, the patient may experience an
increased tolerance to the dose of the drug10 and dependency.14 Risk for dependency
may also be linked to the type of first benzodiazepine used and dose escalation
schedule.14
Reports such as these have led the FDA to announce extensive changes to the
requirements for the package labeling and medication guide of nearly four hundred
products which contain opioid analgesics, including cough products or
benzodiazepines. The new materials will contain the FDA’s most serious warning –
the boxed warning, to indicate the serious risks associated with the use of these
medications. In addition to the packaging changes, this announcement was
accompanied by the publication of a drug safety communication with the intention of
warning prescribers and those taking these medications about the dangers of
concomitant use of these classes of medications.1
The Rhode Island Prescription Drug Monitoring Program affords physicians
and pharmacists alike the ability to actively manage their patients, and make
prescribing decisions based on a comprehensive look at the patient’s prescription
history. The focus of this study was to quantify the number of patients in Rhode
Island who were prescribed concomitant therapy with opioids and benzodiazepines in
2015 and determine if there were patient level or prescription level predicators that
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indicated a patient was more likely to be prescribed concomitant therapy.

6

CHAPTER 3

METHODOLOGY

Study design
A cross sectional observational study was conducted using de-identified pharmacylevel data obtained from the Rhode Island Prescription Drug Monitoring Program
(PDMP). For all patients who received benzodiazepine or opioid medications in 2015,
the percentage who received a dispensing for both categories of drugs was determined,
and characteristics associated with use of both opioid and benzodiazepine medications
were identified.
Data Source
The Rhode Island PDMP database includes pharmacy-level data for all prescriptions
filled for schedule II to IV medications at Rhode Island based pharmacies who hold a
controlled substance registration number. As mandated by state law, all pharmacies
that dispense schedule II-IV medications to individuals who are “not an inpatient of a
hospital, correctional institution or nursing facility” are required to electronically
report 19 data elements to the PDMP within 72 hours of filling the prescription. The
data set does not include medications dispensed to patients of outpatient methadone
maintenance programs. A de-identified subset of PDMP data was used, which
included the following variables: age, gender, payer, date of prescription fill, the
number of days covered by the prescription, medication name, and a de-identified
prescriber drug enforcement administration identification number.
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Study population:
The study population was comprised of patients of any age who filled a prescription
for an opioid medication, a benzodiazepine, or both in Rhode Island, during 2015.
Patient identification:
Inclusion/exclusion criteria
The following patients were included: A.) Patients, of any age, who filled at least one
prescription for oxycodone, hydrocodone, morphine, oxymorphone, hydromorphone,
tapentadol, methadone, pentazocine, butorphanol, meperidine, levorphanol or codeine
tablets, or fentanyl patches, totaling at least a 30 days’ supply during 2015. Patients
who filled prescriptions for buprenorphine or dose forms of opioids which suggest
cancer treatment (such as fentanyl lozenges) were excluded; and B. Patients who filled
at least one prescription for any benzodiazepine drug.
Study variables:
Outcome variables:
The primary outcome measure was the concomitant use of opioid medications and
benzodiazepines. This variable was defined as the receipt of any benzodiazepine and
opioid pharmacy dispensing having a days’ supply which overlapped by at least 1 day.
Independent variables:
Demographic variables included age (and age group), gender, payment type (including
cash and insurance), number of unique opioid and/or benzodiazepine prescribers, if the
patient received any prescriptions from the top five, ten and twenty five percent of
opioid prescribers in Rhode Island (percentage was determined by the total number of
opioid prescriptions written in 2015 by the prescriber in relation to the total number of
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opioid prescriptions in 2015), type of opioid medication(s) prescribed (short acting
versus long acting, and also chemical type (oxycodone, hydrocodone, morphine,
oxymorphone, hydromorphone, tapentadol, methadone, pentazocine, butorphanol,
meperidine, levorphanol, codeine and fentanyl), total days’ supply, total number of
dispensings for controlled substances of any type (CII-CIV), whether the drugs of
interest were prescribed by the same or different prescribers, if the patient was a high
utilizer of multiple pharmacies or prescribers, and the concurrent use of stimulants.
Statistical analysis:
A descriptive analysis was conducted to identify the overall frequency and percentage
of each variable included in the study. Each independent variable was compared with
concomitant use, sole use of opioids, sole use of benzodiazepines and nonconcomitant use of both opioids and benzodiazepines. We conducted a student t-test
for continuous variables, and a Chi-square test for categorical variables to determine
the statistical significance of differences between the four outcome groups.
After the initial descriptive analysis, the outcome groups were collapsed into
one dichotomous variable: concomitant use (sole use of opioids, sole use of
benzodiazepines and non-concomitant use of both opioids and benzodiazepines groups
were combined to represent non-concomitant use.)
Univariate logistic regression analysis was conducted to evaluate the
association between each independent variable with the dependent variable and
identify the significant risk factors of concomitant use of opioid and benzodiazepine
medication. A predictive multivariate logistic regression model was then built using a
backward stepwise approach with all significant independent variables identified from
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the univariate logistic regression. Independent variables associated with combined use
of opioid and benzodiazepine drugs at P<0.2 (for any strata) were retained in the
model. Diagnostic tests for collinearity were performed between independent
variables, 2-way interactions were assessed, and diagnostics of model fit were
examined, as guided by Akaike information criterion and the Hosmer Lemeshow test.
The measure of association between outcome and each independent variable was
determined by computing the odds ratio with a 95% confidence interval. Bonferroni
Correction was applied for multiple or pairwise comparisons for independent variables
with multiple levels.
A sensitivity analyses was conducted. Specifically, the definition of
concomitant use of opioid and benzodiazepine medications was expanded to include 0,
≥2, or ≥3 concomitant days of opioid and benzodiazepine prescriptions. For zero
concomitant days, the gap between prescriptions was not greater than one day.
Finally, a subgroup analyses was conducted to examine whether the significant
risk factors for concomitant use of opioids and benzodiazepines differed by gender.
Statistical analyses were conducted in SAS 9.4 (SAS software Inc., Cary, NC).
The statistical significance level was set at P<0.05. This protocol was submitted to the
University of Rhode Island Institutional Review Board for review, and classified as
not human subjects research.

10

CHAPTER 4

FINDINGS

Hypothesis 1:
The PDMP database that we analyzed was comprised of 2,516,314 claims for
409,740 unique individuals, from 2015 and 2016. To identify our population of
interest, we first reduced the database to claims from 2015 only, identifying 1,289,651
claims for 364,128 unique individuals. We then limited the database to include
prescriptions for opioids and benzodiazepines of any duration. The data were then
arranged at the patient level only, in order to tally days’ supply of each drug class and
identify additional patients for exclusion; this yielded 326,785 unique individuals who
had opioid use of any duration and/or benzodiazepine use. We then removed any
patient who had missing prescription information data, including drug NDC, date of
fill, or days’ supply. We also identified individuals who we presumed to be receiving
opioids to manage cancer pain, based on the type of fentanyl prescriptions (e.g.
lozenge). This further reduced our database to 297,594 unique individuals. Finally,
we excluded individuals who did not meet the threshold of 30 days of opioid use in
2015. Our resulting database included 139,410 unique individuals. Of those included,
34,825 (25%) patients filled opioid prescriptions totaling at least 30 days and no
benzodiazepine prescriptions, 81,062 (58.1%) patients filled a benzodiazepine
prescription and no opioid prescriptions, 1,871 (1.3%) patients filled opioid
prescriptions totaling at least 30 days and a benzodiazepine prescription which did not
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overlap with the opioid prescription. These three groups of patients were combined to
represent the non-concomitant use level of the dichotomized concomitant use outcome
variable. Additionally, 21,652 (15.5%) patients filled opioid prescriptions totaling at
least 30 days, and a benzodiazepine prescription which overlapped the opioid
prescription by at least one day. This group was labeled the concomitant use group.
See Figure 1.
Table 1 provides the frequency and percentage of the independent variables by
each of the four groups outlined above. The majority of our study population was
female (63%) and the average age was 55 years (SD 18.7). Most had commercial
insurance (65%), filled prescriptions at fewer than 4 pharmacies (94.2%) and had
fewer than 4 prescribers (89.4%). The average number of prescriptions for controlled
substances per patient during 2015 was 6.7 (SD 7.3). Each independent variable was
compared with each outcome of interest; all variables were statistically significantly
associated with differences among the four outcomes groups, with the exception of
gender. Subsequent multivariable analysis was performed using the dichotomized
concomitant use outcome variable.
For the multivariate analysis, the continuous variable age was not included,
since both age variables were significant in the univariate analysis. Gender was not
included since it was insignificant in the univariate analysis. Overall, the covariates
included in the multivariate model remained statistically significant.
A diagnostic test for collinearity did not reveal any collinear covariates. We
also assessed for 2-way interactions between age and all covariates, and total number
of prescriptions and all covariates. Significant interaction was seen between age and

12

total number of controlled substance prescriptions, number of prescribers and
stimulant use, and also between total number of prescriptions and pharmacy
utilization, payment type and stimulant use. These interactions were then entered in
the model. After running subsequent models, pharmacy utilization was removed as it
was no longer significant. The model fit was not improved by the inclusion of the
interaction terms, according to the Hosmer and Lemeshow test (p <.0001), therefore
the model findings without the interaction terms is presented in Table 2.
Results from the multivariable model revealed that patients who were 45-64
years of age (OR 1.326, 95% CI 1.259-1.398) or greater than 64 years of age (OR
1.85, 95% CI 1.75-1.96) were more likely to be prescribed concomitant opioid and
benzodiazepine prescriptions than younger patients. Those who received controlled
substance prescriptions from less than or equal to three prescribers (OR 0.257, 95% CI
0.246-0.268) were less likely to be prescribed concomitant opioid and benzodiazepine
prescriptions than those who received controlled substance prescriptions from greater
than 3 prescribers. However, patients who paid for the most recent prescription using
health insurance (commercial health insurance OR 1.003, 95% CI 0.943-1.067; public
health insurance OR 1.108, 95% CI 1.035-1.185; other health insurance OR 3.684,
95% CI 3.249-4.177), and did not have a least one prescription filled for a stimulant
(OR 3.285, 95% CI 3.021-3.572), had increased odds of being prescribed
benzodiazepines and opioids concomitantly. Additionally, each additional prescription
for a controlled substance that a person was prescribed increased the odds that they
were prescribed concomitant therapy by 12 percent (OR 1.12, 95% CI 1.118-1.122.
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Hypothesis 2:
Of those individuals who were prescribed at least one instance of concomitant
prescriptions, the average number of opioid, benzodiazepine and controlled substance
prescriptions and the most commonly prescribed opioid and benzodiazepine
medications were identified. The most commonly prescribed opioids were oxycodone
and hydrocodone, with roughly 50% of the concomitant use group being prescribed at
least one of these medications (54% and 49%, respectively). On average, individuals
who received concomitant opioid and benzodiazepine prescriptions, received 10
prescriptions for opioids (SD 7) and 7 prescriptions for benzodiazepines (SD 5). See
Table 3.
We analyzed prescribers by de-identified DEA number, and determined the top
25%, 10% and 5% of opioid prescribers, by prescription volume. In the concomitant
use group, 21,595 (99.7% of the concomitant use group) individuals filled at least one
opioid prescription by a provider who was in the top 25%, 7,359 (34%) filled at least
one opioid prescription by a provider who was in the top 10% and 4,073 (18.8%) filled
at least one opioid prescription by a provider who was in the top 5%. See Table 4.
We conducted a sub group analysis of those receiving concomitant opioids and
benzodiazepines, stratifying by gender. Women, who represented 66% the
concomitant use group, were generally older (36.6% of women were older than 64
years of age versus 29.1% of men, p <0.0001), more likely to pay for prescriptions
using public insurance (28.9% vs 24.3%, p <0.0001), have >3 prescribers (38.7% vs
36.3%, p 0.0007) and fill a greater number of prescriptions for at least one stimulant
(7.5% vs 5.8%, p <.0001). See Table 5.
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Table 6 highlights the significant differences in the type of opioids used
among men and women, and differences in prescribing patterns. Of the most
commonly prescribed opioids, previously mentioned, men filled a greater percentage
of prescriptions than women for oxycodone (59.3% vs 51.3%, p <.0001), morphine
(16% vs 13.8%, p <0.0001) and methadone (2.4% vs 1.7%, p 0.0004). Men also filled
more prescriptions for opioids overall than women (mean 10 prescriptions vs 7
prescriptions, p <.0001). Men were prescribed a greater number of days of opioids
(mean 178.7 days’ vs 172.7 days’ supply, p 0.0025). However, women received a
greater number of days of benzodiazepines (mean 174 days’ supply vs 161.3 days’
supply, p <.0001) and were prescribed concomitant therapy by different prescribers
more frequently than men (60.7% vs 56.9%, p <.0001).
A sensitivity analysis did not reveal any statistically significant differences
among patients who filled concomitant benzodiazepine and opioid prescriptions with
varying degrees of overlapping days. See Appendix 1.
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CHAPTER 5

CONCLUSION

In this state-level analysis of 139,410 individuals we found that overall 15.5%
(21,652) of individuals were prescribed opioid and benzodiazepine prescriptions
concomitantly, which overlapped by at least one day, at least once during 2015. This
figure represents 2.1% of Rhode Islanders during that time. Of those who were
prescribed concomitant therapy, roughly twice as many women (66% to 34%)
received these medication types concomitantly as compared with men. Our results
agree with published findings from the analysis of 2013-2014 data obtained from the
Texas PDMP and a national data sample which mimicked the data available in a
PDMP for 2015. These analyses presented similar trends of potentially inappropriate
concurrent prescribing of opioids and benzodiazepines (among other potentially
inappropriate drug combinations.)
In analyzing data from the Texas PDMP, researchers found that 15.99% of
controlled substance users were prescribed at least one instance of potentially
inappropriate concurrent combinations of drugs. Their analysis included a greater
number of inappropriate drug combinations than our analysis, however they found that
opioids were the most prevalent drug class involved in potentially inappropriate
concurrent use combinations (96% of individuals who were prescribed at least one
instance of potentially inappropriate concurrent combinations of drugs). They
determined that risk factors for concurrent use of inappropriate drug combinations
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included having a prescription for opioids, being greater than 18 years old, and using a
controlled substance for greater than 30 days.15
Another study which found similar results, compared laboratory drug
screening test result data to provider supplied prescription information, for both
prescriptions written by the clinician who order the drug screening, and other drugs
that the patient was prescribed, which were obtained from the PDMP. All subjects
included in this study were prescribed either a benzodiazepine and/or an opioid. This
study concluded that concomitant use of benzodiazepines and opioids were more
common in women (P<0.01), and that this result was driven by the increased number
of benzodiazepine prescriptions which women received (32.7% vs 23.5%). They also
found that the use of benzodiazepines, opioids and the concomitant use of both drugs
increased with age.16
We also found that older age increases risk for concomitant opioid and
benzodiazepine use, which is supported by findings that older adults may suffer from
more chronic pain,17 and are prescribed benzodiazepines for a range of maladies
including, insomnia and anxiety.18 We theorized that an individual who was
prescribed concomitant opioid and benzodiazepine drugs was more likely to have a
greater number of prescribers; this theory was confirmed by our findings. Patients
who saw greater than two prescribers were more likely to receive concomitant therapy.
These patients may have more complicated medical conditions requiring them to see
more physicians, but the care may not be well coordinated. Another potential
explanation of this finding is timing of the implementation of the PDMP with relation
to our study year. One goal of implementation is to encourage prescribers to consult
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the database prior to prescribing medications, however through the end of 2015 (the
year of the study), only about 40% of prescribers had registered with the PDMP.
Further analysis with subsequent years of data may find different results; as of
September, 2016, 100% of Rhode Island prescribers were registered with the PDMP.19
Lastly, patients who were prescribed stimulant medications were less likely to be
prescribed opioids and benzodiazepines as concomitant therapy. We included
stimulant use as a covariate due to its potential for abuse. While stimulant use (and
subsequent abuse) has been historically seen in younger populations,20 stimulant
dependence and abuse has been reported in older adult populations as well.21
Much of the published literature surrounding concomitant use of
benzodiazepines and opioids discusses changes in prescribing patterns over time,22 the
detrimental effects of concomitant use of these drugs, including death,5,11,23,24 and
socio-economic factors that predict concomitancy.13,22,25 While these topics are
important and relevant to the current climate of pharmaceutical prescribing, these are
not factors that we can consider with the data utilized in our study. In addition to its
primary purpose as a real-time tool to aid prescribers and pharmacists in making the
best decisions for their patients with timely information about patients’ prescription
history, PDMP data provide opportunity for state-wide evaluation of patterns of
controlled substance use, such as our study, that inform public health efforts to
promote safe and evidence-based use of higher-risk medications.

Limitations:
While the PDMP dataset lacks certain basic demographic information, such as
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race/ethnicity, other variables which are captured in the database have been reported
as predictors in published literature and were consistent with our findings, including
age, and a single provider who writes concomitant prescriptions.22
This study has several limitations in its current state, some of which can be
addressed in future analysis, and others that are limitations of the dataset. Limitations
which will be addressed in subsequent analysis are identifying and determining the
significance of other prescribed scheduled medications, identifying prescribers who
write the most prescriptions for opioids, benzodiazepines, and the concomitant use of
these medications. It is possible that some providers are unaware of their patient’s
concomitant therapy while others may be prescribing it knowingly. Further sub-group
analyses will provide more insight into these factors.
Limitations that we cannot address through a more thorough analysis include a
lack of diagnosis information, use of non-scheduled drugs, race, socio-economic status
attributes including income, education, transportation, housing status, marital status –
all which may be of interest but are beyond the scope of this research and database.
We excluded patients who we determined to be receiving end-of-life care or cancer
treatment, without diagnosis code this determination was based on the type of
prescription that a patient filled. It is possible that we over or under-estimated the
number of patients with these conditions.
We conclude that there are predictive factors that can be observed in pharmacy
level data to determine if a patient is at a higher risk for being prescribed concomitant
benzodiazepine and opioid therapy. These factors are age greater than or equal to 45
years, using health insurance to pay for controlled substance prescriptions (rather than
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cash) and receiving controlled substance prescriptions from greater than two
prescribers.
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APPENDICES
Table 1. Characteristics of 139,410 patients who received opioid and/or
benzodiazepine prescriptions from RI pharmacies in 2015
Concomitant Use

Opioid Only

Benzodiazepine
Only

Dual use no
overlap

(% of Total)

(% of Total)

(% of Total)

(% of Total)

n = 21652 (15.5)

n = 34825 (25)

n = 81062 (58.1)

n = 1871 (1.3)

N = 139410

59.2 (15.7)

59.4 (17.2)

51.4 (19.3)

57.6 (17.1)

54.8 (18.7)

<19

47 (<1)

491 (1.4)

3705 (4.6)

9 (<1)

4253 (3)

19 -24

117 (<1)

350 (1)

3910 (4.8)

32 (<1)

4413 (3.2)

25 – 44

3474 (16)

5313 (15.3)

20287 (25)

389 (20.1)

29539 (21.1)

Characteristic

Total
p value

Age
Age Mean, (SD)

<0.00011

Age Group, N (%)

<0.0001
45 – 64

10642 (49.2)

15773 (45.3)

32462 (40.1)

801 (42.8)

59909 (42.8)

> 64

7372 (34.1)

12898 (37)

20698 (25.5)

640 (34.21)

41780 (29.9)

Male

7363 (34)

16304 (46.8)

27062 (33.4)

660 (35.3)

51598 (36.9)

Female

14288 (66)

18515 (53.2)

53977 (66.6)

1211 (64.7)

88266 (63.1)

Cash

1881 (8.7)

3570 (10.2)

11302 (13.9)

204 (10.9)

16916 (12.1)

Public

5914 (27.3)

10255 (29.2)

13298 (16.4)

457 (24.4)

30018 (21.5)

Gender, N (%)

<0.0001

Payment type, N (%)

<0.0001
Commercial
Other

13152 (60.7)

20456 (58.2)

56007 (69.1)

1163 (62.2)

90877 (65)

705 (3.3)

888 (2.5)

454 (<1)

47 (2.5)

862 (2.5)

Total Number of prescribers (all opioids and/benzodiazepines) N (%)
<= 3

13456 (62.2)

33867 (96.3)

80283 (99)

1348 (72)

125118 (89.4)

>3

8196 (37.8)

1301 (3.7)

779 (1)

1523 (28)

14776 (10.6)

<0.0001

Total Number of pharmacies used to fill opioid and/or benzodiazepine prescriptions, N (%)
<= 3

17572 (81.2)

31882 (91.6)

80184 (98.9)

1673 (89.4)

131727 (94.2)

>3

4080 (18.8)

2943 (8.4)

878 (1.1)

198 (10.6)

8168 (5.8)

6.2 (7.0)

9.8 (7.7)

6.7(7.3)

5205 (6.4)

125 (6.7)

7794 (5.6)

<0.0001

Total Prescriptions for controlled substances, Mean (SD)
24.2 (15.7)

10.5 (9.9)

<0.00011

Stimulant Use, Filled at least one prescription in 2015, N (%)
1498 (6.9)

950 (2.7)

1

Performed Student t-test using Concomitant use compared to all other categories combined

21

<0.0001

Table 2. Adjusted odds of receiving concomitant opioid and benzodiazepine
prescriptions, and compared with using either medication separately (N = 139,410).
Characteristic
Age (Ref = 25-44)
<= 18
19 – 24
45 – 64
>= 65

Odds Ratio

95% CI1

p Value

0.231
0.343
1.326
1.85

0.17
0.28
1.259
1.75

0.32
0.43
1.398
1.96

<.0001
<.0001
<.0001
<.0001

Commercial Insurance

1.003

0.943

1.067

0.9268

Public Insurance

1.108

1.035

1.185

0.003

Other

3.684

3.249

4.177

<.0001

0.257

0.246

0.268

<.0001

1.119

1.117

1.121

<.0001

3.226

2.967

3.509

<.0001

Payment Type (Ref = Cash)

Unique Prescribers (Ref = > 3 Prescribers)
<= 3 Prescribers
Total Number of
Prescriptions
Stimulant Use
(Ref = None)
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Table 3. Opioid and Benzodiazepine Use in the Concomitant Use Group:
Medication Type, 1 Number of Prescriptions, Total Days’ Supply and Patients
receiving Medication from Different Prescribers
Medication N (%)
Oxycodone

11,694 (54)

Hydrocodone

10617 (49)

Morphine

3143 (14.5)

Codeine

1905 (8.8)

Fentanyl

1159 (5.4)

Hydromorphone

955 (4.4)

Methadone

426 (2)

Oxymorphone

116 (<1)

Tapentadol

93 (<1)

Pentazoncine
Buterophanol
Meperidine
Levorphanol
Benzodiazepine Type, N (%)
Alprazolam
Lorazepam
Clonazepam
Diazepam
Temazepam
Clorazepate
Chlordiazepoxide
Triazolam
Oxazepam
Flurazepam
Estrazolam

23 (<1)
23 (<1)
20 (<1)
1 (<1)
6518 (28.2)
5618 (24.3)
5602 (24.2)
4663 (20.2)
515 (2.2)
91 (<1)
53 (<1)
46 1)
18 (<1)
12 (<1)
3 (<1)

Average number of opioid prescriptions by duration of action, Mean (SD)
Short Acting
Long Acting

9.3 (6.7)
1.7 (4.5)

Average Number of Prescriptions, Mean (SD)
Opioids
Benzodiazepines

10 (7)
7 (5)

Average Days of Supply, Mean (SD)
Opioids
Benzodiazepines
Overlapping days

174.8 (117.2)
169.7 (125)
10.2(10.2)

Different Prescribers, N (%)
At least one instance of concomitant opioid and benzodiazepine
prescriptions were prescribed by different prescribers
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12861 (59.4)

Table 4. Receipt of an Opioid Prescription by a top 25%, 10% and 5% Opioid
Prescriber by Total Prescription Volume, in the Concomitant Use Group.
Patient filled at least one prescription written by a prescriber who was in the top
25% of opioid prescribers
21595 (99.7)
10% of opioid prescribers
7359 (34)
5% of opioid prescribers
4073 (18.8)

Table 5. Opioid and Benzodiazepine Use in the Concomitant Use Group, Stratified
by Gender: Medication Type,1 Number of Prescriptions, Total Days’ Supply.
Male
Female
p Value
n = 7363
n = 14288
Age
Age Mean, Mean (SD)
57.7 (14.3)
60.04 (16.3)
<0.0001
Age Group, N (%)
<19
19 (<1)
28 (<1)
19 -24
45 (<1)
72 (<1)
25 – 44
1190 (16.2)
2283 (16)
<0.0001
45 – 64
3968 (53.9)
6674 (46.7)
> 64
2141 (29.1)
5231 (36.6)
Payer, N (%)
Cash
626 (8.5)
1255 (8.8)
Public
1792 (24.3)
4122 (28.9)
<0.0001
Commercial
4691 (63.7)
8460 (59.2)
Other
254 (3.5
451 (3.2)
Number of Prescribers, N (%)
<= 3
4691 (63.7)
8764 (61.3)
0.0007
>3
2672 (36.3)
5524 (38.7)
Number of Unique Pharmacies, N (%)
<= 3
5924 (80.5)
11648 (81.5)
0.0572
>3
1439 (19.5)
2640 (18.5)
Total Prescriptions, Mean (SD)
Any prescriptions reported in the
24.2 (15.7)
24.0 (15.6)
0.0015
PDMP
Stimulant Use, N (%)
Filled at least one prescription in
424 (5.8)
1074 (7.5)
<0.0001
2015
Total Prescriptions, Mean (SD)
23.6 (15.4)
24.5 (15.8)
<0.0001
1

One case was removed for gender variable not recorded
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Table 6. Opioid and Benzodiazepine Use in the Concomitant Use Group, Stratified
by Gender: Chemical Type, Number of Prescriptions, Total Days Supply1 and
Inconsistent Prescribers.
Chemical Type, N (%)
Male
Female
p Value
Oxycodone
4363 (59.3)
7330 (51.3)
<0.0001
Morphine
1175 (16)
1968 (13.8)
<0.0001
Codeine
476 (6.5)
1429 (10)
<0.0001
Methadone
179 (2.4)
247 (1.7)
0.0004
Average number of prescriptions by duration of Action, Mean (SD)
Long Acting
2.0 (4.8)
1.6 (4.3)
<0.0001
Average Number of Prescriptions, Mean (SD)
Opioids
10 (7)
7.4 (4)
<0.0001
Benzodiazepines
6.6 (5)
7.1 (5.1)
<0.0001
Average Days of Supply, Mean (SD)
For Opioids
178.7 (119.5)
172.7 (115.9)
0.0025
For Benzodiazepines
161.3 (126.9)
174 (123.8)
<0.0001
Different Prescribers, N (%)
At least one instance of
concomitant opioid and
benzodiazepine
4188 (56.9)
8673 (60.7)
<0.0001
prescriptions were
prescribed by different
prescribers
1

Significant independent variables included
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Figure 1. Flow chart for selection criteria of study participants

Initial PDMP Database

N=
409,740

2015 Only

n=
364,128

Receipt of
Benzodiazepine and/or
Opioid Prescriptions

n=
326,785

Complete Prescription
Claim information, did
not receive prescription
for opioid to treat cancer
pain

n=
297,594

Received
benzodiazepines and/or
>= 30 days of opioids

n=
139,410

Final Outcome Groups1

n = 21,652

n = 34,825

1

n = 81,062

n = 1,871

From left to right: Concomitant use of opioids and benzodiazepines, opioid use only, benzodiazepine
use only, non-concomitant use of opioids and benzodiazepines.
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Appendix 1. Sensitivity Analysis of Number of Days of Overlapping
Benzodiazepine and Opioid Prescriptions Dispensed in RI pharmacies in 2015, in
the Concomitant Use Group
Concomitant
Use1

No Overlap2

At least 2 days
of overlap

At least 3 days of
overlap

n = 21652

n = 22136

n = 21276

n = 20890

59.2 (15.7)

59.2 (15.7)

59.4 (17.2)

51.4 (19.3)

p Value

Age*
Age Mean
Age Group
<19

47 (<1)

48 (<1)

46 (<1)

44 (<1)

19 -24

117 (<1)

121 (<1)

113 (<1)

108 (<1)

25 – 44

3474 (16)

3550 (16)

3397 (16)

3314 (15.9)

45 – 64

10642 (49.2)

10873 (49.1)

10457 (49.2)

10286 (49.2)

7372 (34.1)

7544 (34.1)

7263 (34.1)

7138 (34.2)

> 64
Gender
Male
Female
Payer

7363 (34)

7572 (34.2)

7213 (33.9)

7046 (33.7)

14288 (66)

14563 (65.8)

14062 (66.1)

13843 (66.3)

0.96

>.99

0.98

Cash

1881 (8.7)

1924 (8.7)

1851 (8.7)

1819 (8.7)

Public

5914 (27.3)

6058 (27.4)

5819 (27.4)

5746 (27.5)

Commercial

13152 (60.7)

13435 (60.7)

12915 (60.7)

12650 (60.6)

719 (3.3)

691 (3.3)

675 (3.2)

13456 (62.2)

13758 (62.1)

13248 (62.3)

13025 (62.4)

>3
8196 (37.8)
Pharmacy Utilization

8378 (37.9)

8028 (37.7)

7865 (37.7)

17572 (81.2)

17988 (81.3)

17252 (81.1)

16929 (81)

>3
4080 (18.8)
Total Prescriptions*

4148 (18.7)

4024 (18.9)

3961 (19)

24.2 (15.7)

24.0 (15.6)

24.4 (15.7)

24.6 (15.7)

>.99

1498 (6.9)

1514 (6.8)

1482 (7)

1460 (7)

0.93

Other
705 (3.3)
Number of prescribers
<= 3

<= 3

>.99

0.97

0.94

Stimulant Use
Filled at
least one
prescription in
2015
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